3
Indication details
- Control Arm
- Enzalutamide or abiraterone (crossover allowed)
- Therapeutic Indication
- Treatment of adult patients with mCRPC and BRCA1/2 mutations (germline and/or somatic) who have progressed following prior therapy that included a new hormonal agent
- Tumour Type
-
Genitourinary Cancers
- Tumour Sub-type
- Prostate cancer
- Tumour Stage
- Metastatic
- Tumour Sub-Group
- BRCA mutation Patients with ≥1 alteration in BRIP1, BARD1, CDK12, CHEK1, CHEK2, FANCL, PALB2, PPP2R2A, RAD51B, RAD51C, RAD51D or RAD54L
- Trial Name
- PROfound
- NCT Number
- NCT02987543
- Trial Phase
- Phase III
Approval details
- FDA Approval
- FDA approval May 2020
Primary Outcome(s)
- Primary Outcome(s)
- PFS
- Evaluated Outcome
- PFS
- Form(s)
- Form 2b
Outcome Data
- PFS Control
- 3.5 months
- PFS Gain
- 2.3 months
- PFS HR
- 0.49 (0.38-0.63)
- OS HR
- NS immature
Adjustments
- QoL Comment
-
No QoL benefit
- Toxicity Comment
-
>10% incremental discontinuation due to AEs
Score (after adjustments)
- Preliminary non-curative score
-
3
- Non-curative score
-
3
Scorecard details
- ESMO-MCBS version
- ESMO-MCBS v1.1
- Scorecard ID
- 391
- Scorecard version
- 1
- Issue date
- 10.08.2023
- Last update
- 15.11.2024